About
Bispecific Antibodies
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibodyVirginia, DC, DE & Maryland
Clinical Trials (51)
View allTotal Trials
51
As Lead Sponsor
41
As Collaborator
10
Total Enrollment
5,135
By Phase
PHASE2: 15PHASE1: 22PHASE1/PHASE2: 6PHASE2/PHASE3: 3PHASE3: 2NA: 1
By Status
COMPLETED: 24TERMINATED: 12RECRUITING: 6ACTIVE_NOT_RECRUITING: 4WITHDRAWN: 2NO_LONGER_AVAILABLE: 2NOT_YET_RECRUITING: 1
Clinical Trials Pipeline49 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Today
Hover over trial bars to see details
Recent Trials
NCT07071961Collaborator
Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
PHASE2Not yet recruiting
16 participants
Started: Jan 1, 2026 · Completed: May 1, 2029
NCT06730347Lead Sponsor
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
PHASE2Recruiting
60 participants
Started: May 1, 2025 · Completed: Aug 31, 2027
NCT06723236Lead Sponsor
A Study of MGC028 in Participants With Advanced Solid Tumors
PHASE1Recruiting
124 participants
Started: Feb 13, 2025 · Completed: Apr 30, 2027
NCT06227546Collaborator
MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer
PHASE2Active, not recruiting
9 participants
Started: Apr 15, 2024 · Completed: May 31, 2026
NCT06242470Lead Sponsor
A Study of MGC026 in Participants With Advanced Solid Tumors
PHASE1Recruiting
250 participants
Started: Mar 6, 2024 · Completed: Oct 31, 2028
Locations (1)
Headquarters
Rockville, MD, United States
Map
Loading map...